Natalizumab for active Crohn's disease [2] (multiple letters)

New England Journal of Medicine

Volumn 348, Issue 16, 2003, Pages 1599-

  Lew, Edward A ^a   Stoffel, Elena Martinez ^a   Subrata, Ghosh ^b   Palmer, Tanya ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Imperial College of Medicine   (United Kingdom)

^c Elan Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; NATALIZUMAB;

CLINICAL TRIAL; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; HUMAN; LETTER; OUTCOMES RESEARCH; PRIORITY JOURNAL; REMISSION; SAMPLE SIZE;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION;

EID: 0037451911     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200304173481615     Document Type: Letter

References (0)